|
|
News Breaks
|
December 21, 2011
|
| 09:11 EDT |  | AZN, DVAX |
| theflyonthewall.com: | Dynavax, AstraZeneca agree to advance AZD1419 | | Dynavax Technologies (DVAX) and AstraZeneca (AZN) announced their decision to advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into IND-enabling preclinical toxicology studies. These toxicology studies are scheduled to be the first module of work performed by Dynavax under the recently amended collaboration agreement for the clinical development of AZD1419. Development expenses will be fully funded by AstraZeneca, and Dynavax will receive payment of $2.6M to begin the studies. :theflyonthewall.com |
|
|
News For DVAX;AZN From The Last 14 Days Check below for free stories on DVAX;AZN the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 24, 2012
|
| 17:52 EDT |  | AZN |
|
|
May 15, 2012
|
| 10:09 EDT | | AZN |
| | 07:24 EDT | | AZN |
| | 06:10 EDT | | AZN |
|
|
|
|
|
Subscribe for More Information